Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis

NCT ID: NCT02105818

Last Updated: 2017-04-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

64 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-03-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is the validation of a newly developed self-report questionnaire which aims at determining the prevalence, location and intensity of SWAllowing difficulties with drug intake, and describing the impact on MEdication regimen focusing on COping strategies (SWAMECO).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims at investigating a cohort of patients with diagnosed systemic sclerosis using the newly developed self-report SWAMECO-questionnaire.

The self-report questionnaire is sub-divided into four sections: detection of swallowing difficulties, coping strategies, risk factors to develop swallowing difficulties and adherence to medication.

This study involves patients with systemic sclerosis. Systemic sclerosis often is accompanied by swallowing disorders which may lead to issues in handling medication regimen with risks for patient safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systemic Sclerosis Deglutition Disorders Adherence to Medication Regime Coping Behaviour Scleroderma, Systemic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Systemic sclerosis

Patients with diagnosed systemic sclerosis treated in the Reha Rheinfelden, Switzerland (European Centre for the Rehabilitation of Scleroderma).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \>18 years
* diagnosis for systemic sclerosis
* treated in the Reha Rheinfelden
* signed informed consent
* german language skills

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Basel

OTHER

Sponsor Role collaborator

Reha Rheinfelden

OTHER

Sponsor Role collaborator

Kurt Hersberger

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kurt Hersberger

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kurt Hersberger, Prof

Role: STUDY_CHAIR

Pharmaceutical Care Research Group, University of Basel, Switzerland

Markus Messerli, MSc

Role: STUDY_DIRECTOR

Pharmaceutical Care Research Group, University of Basel, Switzerland

Michael Buslau, PD MD

Role: PRINCIPAL_INVESTIGATOR

Reha Rheinfelden, Switzerland

Rebecca Wysser, BSc

Role: PRINCIPAL_INVESTIGATOR

Pharmaceutical Care Research Group, University of Basel, Switzerland

Isabelle Arnet, PhD

Role: PRINCIPAL_INVESTIGATOR

Pharmaceutical Care Research Group, University of Basel, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Reha Rheinfelden

Rheinfelden, Canton of Aargau, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Marquis J, Schneider MP, Payot V, Cordonier AC, Bugnon O, Hersberger KE, Arnet I. Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. Int J Clin Pharm. 2013 Dec;35(6):1130-6. doi: 10.1007/s11096-013-9836-2. Epub 2013 Aug 21.

Reference Type BACKGROUND
PMID: 23963541 (View on PubMed)

Schiele JT, Quinzler R, Klimm HD, Pruszydlo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013 Apr;69(4):937-48. doi: 10.1007/s00228-012-1417-0. Epub 2012 Sep 29.

Reference Type BACKGROUND
PMID: 23052416 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.pharmacare.unibas.ch

Homepage of the Pharmaceutical Care Research Group, University of Basel, Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SWAMECO_1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Primary Sjögren Syndrome
NCT01989819 COMPLETED
Taking Charge of Systemic Sclerosis
NCT02494401 COMPLETED NA
Effects of FT011 in Systemic Sclerosis
NCT04647890 COMPLETED PHASE2